Genetic Subtypes and Status of Transmitted Drug Resistance of HIV/AIDS Patients in Sichuan

LIU Huan-xia; HE Sheng-hua; ZHOU Rui-feng; HE Yuan-hong; YANG Tong-tong; YAO Yuan

doi:10.12182/20220960206

Volume 53 Issue 5

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) > 2022 > 53(5): 851-856. > DOI: 10.12182/20220960206

LIU Huan-xia, HE Sheng-hua, ZHOU Rui-feng, et al. Genetic Subtypes and Status of Transmitted Drug Resistance of HIV/AIDS Patients in Sichuan[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(5): 851-856. DOI: 10.12182/20220960206

Citation:

PDF (481 KB)

Genetic Subtypes and Status of Transmitted Drug Resistance of HIV/AIDS Patients in Sichuan

Infectious Disease Department One, Chengdu Public Health Clinical Medical Center, Chengdu 610061, China

More Information

Corresponding author:
HE Sheng-hua, E-mail: 13198552429@163.com
Received Date: December 06, 2021
Revised Date: June 08, 2022
Available Online: September 25, 2022
Published Date: September 19, 2022

Abstract

Abstract

Objective To investigate the distribution characteristics of the HIV genetic subtypes and the status quo of transmitted drug resistance among HIV/AIDS patients in Sichuan with no previous history of receiving antiretroviral therapy (ART).
Methods Adult HIV/AIDS patients who were hospitalized in Sichuan and who had no previous history of exposure to ART drugs exposure were enrolled. In-house sequencing of the HIV gene was done and phylogenetic tree was constructed to analyze the HIV genetic subtypes. The Stanford HIV drug resistance database was used to make online comparison of the drug resistance mutation sites and to determine the presence or absence of drug resistance, and the type and level of drug resistance.
Results A total of 120 patients were enrolled for the study, and 120 blood samples were collected. The genetic subtypes of 87.5% (105/120) of the samples were successfully amplified. The distribution characteristics of HIV genotype were as follows, CRF01_AE accounted for 46.67% (49/105), CRF07_BC accounted for 39.05% (41/105), and the others genetic subtypes, 14.28% (15/105). There were no significant differences between the different genetic subtypes in sex, age, ethnicity, HIV transmission route, drug resistance, baseline HIV RNA and baseline CD4 (P>0.05). Drug-resistant mutation sites were detected in 25 samples, accounting for 20.83% (25/120) of all samples, with 16.67% (20/120) being potential drug resistance and 4.17% (5/120) being transmitted drug resistance. For the 24 samples found to be resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs), the mutation frequency of V179D/E was the highest. One patient showed resistance to protease inhibitors (PI) and the mutation site was M46I. No nucleoside reverse transcriptase inhibitor (NRTI) or integrase inhibitors (INTI) resistance were found.
Conclusions The main genetic subtypes of HIV/AIDS patients in Sichuan with no previous history of receiving ART were CRF01_AE and CRF07_BC. The incidence of transmitted drug resistance was low. The drug resistance detected in the study was predominantly resistance to NNRTIs. Baseline HIV drug resistance testing is of great significance for formulating effective ART regimens.
- HIV/AIDS patients,
- Antiretroviral therapy,
- Genotypes,
- Transmitted drug resistance

FullText(HTML)

References (20)

References

[1]	PRABHU S, HARWELL J I, KUMARASAMY N. Advanced HIV: Diagnosis, treatment, and prevention. Lancet HIV, 2019, 6(8): e540−e551[2021-11-13]. https://doi.org/10.1016/S2352-3018(19)30189-4.
[2]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版). 中华内科杂志,2021,60(12): 1106–1128. DOI: 10.3760/cma.j.cn112138-20211006-00676
[3]	RYOM L, COTTER A, MIGUEL R D, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10. 0. HIV Med,2020,21(10): 617–624. DOI: 10.1111/hiv.12878
[4]	栗翠林, 肖静, 汪笛, 等. 一线抗病毒治疗失败HIV/AIDS患者治疗前耐药特征分析. 中国艾滋病性病,2021,27(5): 453–456. DOI: 10.13419/j.cnki.aids.2021.05.04
[5]	WANG Z, ZHANG M, ZHANG R, et al. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. BMC Infect Dis,2019,19(1): 313–322. DOI: 10.1186/s12879-019-3927-1
[6]	CLUTTER D S, JORDAN M R, BERTAGNOLIO S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol,2016,46: 292–307. DOI: 10.1016/j.meegid.2016.08.031
[7]	ZUO L, LIU K, LIU H, et al. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017). eClin Med, 2020, 18: 100238[2021-11-13]. https://doi.org/10.1016/j.eclinm.2019.100238.
[8]	中华医学会感染病学分会艾滋病丙肝学组, 中国疾病预防与控制中心. 中国艾滋病诊疗指南(2018版). 中国艾滋病性病,2018,24(12): 1266–1282. DOI: 10.13419/j.cnki.aids.2018.12.26
[9]	MAZZUTI L, MELENGU T, FALASCA F, et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. J Glob Antimicrob Resist, 2020, 20: 298−303[2021-11-13]. https://doi.org/10.1016/j.jgar.2019.08.024.
[10]	MACDONALD V, MBUAGBAW L, JORDAN M R, et al. Prevalence of pretreatment HIV drug resistance in key populations: A systematic review and meta-analysis. J Int AIDS Soc, 2020, 23(12): e25656[2021-11-13]. https://doi.org/10.1002/jia2.25656.
[11]	吴楠楠, 殷明琪, 袁瑞, 等. 我国HIV亚型与耐药性Meta分析. 中华流行病学杂志,2016,37(11): 1546–1554. DOI: 10.3760/cma.j.issn.0254-6450.2016.11.022
[12]	苏迎盈, 刘慧鑫, 吴静, 等. 中国HIV-1基因亚型分布及流行趋势. 中华流行病学杂志,2014,35(10): 1164–1168.
[13]	BBOSA N, KALEEBU P, SSEMWANGA D. HIV subtype diversity worldwide. Curr Opin HIV AIDS,2019,14(3): 153–160. DOI: 10.1097/COH.0000000000000534
[14]	孙伟东, 姜天俊, 黄辉煌, 等. 北京地区HIV-1感染者治疗前耐药特征及2年抗病毒治疗效果研究. 国际病毒学杂志,2020,27(3): 224–227. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.011
[15]	DONG K, YE L, LENG Y, et al. Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Sichuan, China, 2010-2016. Tohoku J Exp Med,2019,247(1): 1–12. DOI: 10.1620/tjem.247.1
[16]	LU X, CHEN S, ZHAO H, et al. Baseline investigation of HIV-1 primary drug resistance among newly diagnosed treatment-naïve HIV-1 individuals in Hebei, China. AIDS Res Hum Retroviruses,2018,34(12): 1083–1089. DOI: 10.1089/AID.2018.0142
[17]	YUAN H, LIU Z, WU X, et al. Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016. Arch Virol,2021,166(9): 2451–2460. DOI: 10.1007/s00705-021-05140-9
[18]	GUO C, WU Y, ZHANG Y, et al. Transmitted drug resistance in antiretroviral therapy-naive persons with acute/early/primary HIV infection: A systematic review and meta-analysis. Front Pharmacol, 2021, 12: 718763[2021-11-13]. https://doi.org/10.3389/fphar.2021.718763.
[19]	龙茂娇, 李健健, 董兴齐. HIV基因型耐药检测在抗病毒治疗中的应用进展. 国际流行病学传染病学杂志,2017,44(5): 333–337. DOI: 10.3760/cma.j.issn.1673-4149.2017.05.011
[20]	LIU Y, LI H, WANG X, et al. Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses. Infect Genet Evol, 2020, 77: 104098[2021-11-13]. https://doi.org/10.1016/j.meegid.2019.104098.

Relative Articles

Supplements (0)

Cited By

Cited by

Periodical cited type(5)

1.	刘梅，朱芮，吴涛，俄尔阿沙木，袁天茹，宋绍芳，刘玲，梁洪远，曹汴川. 凉山州某县未接受抗病毒治疗的HIV-1感染者的耐药情况分析. 中国感染与化疗杂志. 2024(01): 19-24 .
2.	张晓东，胡彦，范吉祥，郭琪，齐晓晨. 吉林省181例病毒学治疗失败的HIV/AIDS患者耐药情况分析. 中国卫生工程学. 2024(05): 589-592+597 .
3.	刘欢霞，何盛华，杨彤彤，蔡琳，程殿霞. 艾滋病住院初治患者HIV-1基因亚型及传播性耐药现状分析. 四川大学学报(医学版). 2024(05): 1295-1300 .
4.	周珍红，邹潇白，张王君，贺健梅，郑军，陈曦. 2021年湖南省HIV-1传播性耐药发生特征分析. 实用预防医学. 2023(05): 524-527 .
5.	丁群一，陈莉萍，周莹. 自愿咨询检测门诊HIV-1新发现感染者治疗前耐药特征和亚型分布. 江苏预防医学. 2023(06): 647-649 .

Other cited types(1)

Get Citation

PDF

XML

Article views (725) PDF downloads (56) Cited by(6)

Genetic Subtypes and Status of Transmitted Drug Resistance of HIV/AIDS Patients in Sichuan

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(1)

Catalog

Export File

Citation

Format

Content